Episteme Prognostics
Episteme Prognostics, Inc.
Episteme Prognostics, Inc. is a pioneering precision medicine company dedicated to revolutionizing pancreatic cancer diagnosis and treatment. By focusing on the development of groundbreaking diagnostic tests, the company aims to enhance therapeutic decisions, ultimately improving patient outcomes. Their innovative technology leverages epigenetic biomarkers to provide critical insights into treatment responses for patients diagnosed with this challenging disease.
Products & Team
PancEpistemeDx
PancEpistemeDx is a proprietary rapid diagnostic test designed specifically for pancreatic cancer patients. This innovative test evaluates tumor samples to predict how patients will respond to first-line chemotherapy treatments. By identifying responders, this test plays a crucial role in personalizing cancer care.
PancEpistemeDx addresses the significant challenge of selecting effective chemotherapy regimens for pancreatic cancer patients by providing predictive insights into their treatment responses. This capability not only improves patient outcomes but also contributes to the overall efficiency of cancer care.
The primary challenges faced by these professionals include the difficulty in determining optimal treatment paths due to the heterogeneous nature of pancreatic cancer and the need for tools that can accurately predict patient responses to existing chemotherapy options.